Levine M N, Bramwell V, Abu-Zahra H, Goodyear M D, Arnold A, Findlay B, Skillings J, Gent M
Ontario Cancer Treatment and Research Foundation, Hamilton, London, Canada.
Br J Cancer. 1992 Jan;65(1):130-2. doi: 10.1038/bjc.1992.25.
A randomised trial has previously been repeated in which 437 women with node positive breast cancer received either a 12-week chemohormonal regimen consisting of cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, adriamycin and tamoxifen or 36 weeks of CMFVP. The present analysis concerns the local recurrence rates for the 122 lumpectomy patients who did not receive breast irradiation. The cumulative rate of local breast recurrence was greater in the 12-week than the 36-week group, P = 0.02. Similarly, in the lumpectomy patients, the cumulative rate of distant recurrence was greater in the 12-week than the 36-week group, P = 0.04. In conclusion, our results suggest that adjuvant chemotherapy impacts on local breast recurrence in a similar manner to other sites in Stage II breast cancer patients treated by lumpectomy without radiation. Despite the use of a conventional 36-week adjuvant chemotherapy regimen, the local breast recurrence rate was substantial.
此前曾重复进行过一项随机试验,437例淋巴结阳性乳腺癌女性患者接受了为期12周的化疗激素方案,该方案包括环磷酰胺、甲氨蝶呤、氟尿嘧啶、长春新碱、泼尼松、阿霉素和他莫昔芬,或接受36周的CMFVP方案。本分析涉及122例未接受乳房放疗的乳房肿瘤切除术患者的局部复发率。12周组的局部乳房复发累积率高于36周组,P = 0.02。同样,在乳房肿瘤切除术患者中,12周组的远处复发累积率高于36周组,P = 0.04。总之,我们的结果表明,辅助化疗对接受乳房肿瘤切除术且未放疗的II期乳腺癌患者局部乳房复发的影响与其他部位相似。尽管使用了传统的36周辅助化疗方案,但局部乳房复发率仍然很高。